I-R&D ye-Sorrento igxile ekuqhubeni izinto ezintsha kwi-COVID-19, unyango lomhlaza, ulawulo olupheleleyo lweentlungu kunye nezifo ezizimelayo.

IiNkqubo eziPhambili	Ukubonisa	Ulungelelaniso	Isigaba I	Isigaba II	Isigaba III/engundoqo	Ukuvunyelwa kwe-FDA
Iinkqubo ze-COVID-19
COVISTIX™ (uxilongo) Uvavanyo lweAntigen olukhawulezayo 0%* Ugunyaziso lokuSebenzisa oluNgxamisekileyo (EUA) eMexico (COFEPRIS), eBrazil (ANVISA), kunye neCE Ephawulwe eYurophu COVIMARK™ (uxilongo) Uvavanyo lweAntigen olukhawulezayo 0%* Isicelo singeniswe e-US naseKhanada kuGunyaziso lokuSebenzisa oluNgxamisekileyo (EUA) VIREX (uxilongo) Kwi-Diagnostic yasekhaya 60.2%* EUA Enabling Studies in Q3 2022 OQORY™ (COVI-MSC) I-ARDS ngenxa ye-COVID-19 kwizigulana zase-ICU 82%* Uvavanyo olubalulekileyo eBrazil                           OVYDSO (Olgotrelvir) Anti-intsholongwane (Ipilisi yomlomo) 40%* Ugonyo lwe-Omicron mRNA Igciwane 20%*
IiNkqubo eziPhambili	Ukubonisa	Ulungelelaniso	Isigaba I	Isigaba II	Isigaba III/engundoqo	Ukuvunyelwa kwe-FDA
immunotherapy
FUJOVEE™ (Abivertinib) I-NSCLC 82%* FUJOVEE™ (Abivertinib) B IiLymphomas zeeseli 60.2%* FUJOVEE™ (Abivertinib) Prostate 20%* PD-L1 (Socazolimab)* I-SCLC 82%* *Ngentsebenziswano neLee's Pharm eTshayina I-PD-L1 (STI-3031)** Ngomhlaza wesibeleko 82%* **E-US kunye nentsebenziswano ne-ImmuneOncia eKorea CD47 Amathumba aqinileyo 40%* I-CD38 DAR-T Multiel Myeloma 40%* CD38 ADC I-Amyloidosis, i-Myeloma emininzi, i-T-ALL, kunye ne-esophageal 40%* TROP2 ADC* Amathumba aqinileyo 40%* Intsholongwane kaSeprehvec™ oncolytic Amathumba aqinileyo; CNS Amathumba 40%* BCMA ADC Amathumba olwelo 20%* Bevacizumab-ADAB™ Umhlaza weSifo seNtsholongwane 40%* Ngentsebenziswano neMayo Clinic Bevacizumab-ADAB™ I-Ovarian Cancer 40%* Ngentsebenziswano neMayo Clinic I-Rituximab-ADAB™ I-B-cell Lymphomas 40%* Ngentsebenziswano neMayo Clinic Sofusa® i-anti-PD-1 I-Cutaneous T-Cell Lymphoma (CTCL), iMelanoma 40%*
IiNkqubo eziPhambili	Ukubonisa	Ulungelelaniso	Isigaba I	Isigaba II	Isigaba III/engundoqo	Ukuvunyelwa kwe-FDA
Ubuhlungu
ZTlido® 1.8% I-Posterpetic Neuralgia - PHN 99.8%* Gloperba® Unyango lweGout (ngomlomo) 99.8%* SEMEXA (SP-102) I-Lumbar Radicular / Sciatica Pain 82%* I-SP-103 (I-Lidocaine Topical System 5.4%) Ubuhlungu be-Acute back 60.2%* I-SP-104 (Idosi eLityazisiweyo yokuGqiswa kweNaltrexone) Fibromyalgia 20%* I-RTX (i-resiniferatoxin) Isitofu se-epidural Intlungu engenakunyanzeliswa kwi-Cancer Advanced 60.3%* Ukubizwa kwenkedama I-RTX (i-resiniferatoxin) Indlela ye-Intra-articular Iintlungu ze-OA zedolo eliPhakathi ukuya kutsho kweMandundu 60.2%*
IiNkqubo eziPhambili	Ukubonisa	Ulungelelaniso	Isigaba I	Isigaba II	Isigaba III/engundoqo	Ukuvunyelwa kwe-FDA
Ukuhanjiswa kweziyobisi kwiLymphatic
Sofusa® I-anti-TNF Amajoni omzimba (RA) 40%* Sofusa® i-anti-PD-1 I-Cutaneous T-Cell Lymphoma (CTCL), iMelanoma 40%* Sofusa® anti-CTLA-4 IMelanoma 40%* Ngentsebenziswano neMayo Clinic

Iinkqubo ze-COVID-19
IiNkqubo eziPhambili (Isalathiso)	Isigaba
COVISTIX™ (uxilongo) FDA EUA COVIMARK™ (uxilongo) FDA EUA VIREX (uxilongo) PH III FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III I-OVYDSO (Olgotrelvir) Ph II Ugonyo lwe-Omicron mRNA Ulungelelaniso

immunotherapy
IiNkqubo eziPhambili (Isalathiso)	Isigaba
FUJOVEE™ (Abivertinib) Ph III FUJOVEE™ (Abivertinib) Ph II FUJOVEE™ (Abivertinib) Ulungelelaniso I-PD-L1 (Socazolimab)* Ph III I-PD-L1 (STI-3031)** Ph III CD47 (Iithumba eziqinileyo) Ph I I-CD38 DAR-T (Multiple Myeloma) Ph I CD38 ADC (I-Amyloidosis, i-Myeloma emininzi, i-T-ALL, kunye ne-esophageal) Ph I TROP2 ADC* (Iithumba eziqinileyo) Ph I Intsholongwane kaSeprehvec™ oncolytic (Iithumba eziqinileyo; CNS Tumors) PH I BCMA ADC (Amathumba olwelo) Ulungelelaniso Bevacizumab-ADAB™ (Umhlaza we-Endometrial) Ph I Bevacizumab-ADAB™ (Umhlaza wesibeleko) Ph I I-Rituximab-ADAB™ (B-cell Lymphomas) Ph I Sofusa® i-anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), iMelanoma) Ph I

Ubuhlungu
IiNkqubo eziPhambili (Isalathiso)	Isigaba
ZTlido® 1.8% (I-Postherpetic Neuralgia - PHN) Ukuvunyelwa kwe-FDA Gloperba® 1.8% Unyango lweGout (ngomlomo) Ukuvunyelwa kwe-FDA SEMEXA (SP-102) Ph III I-SP-103 (I-Lidocaine Topical System 5.4%) Ph II I-SP-104 (Idosi eLityazisiweyo yokuGqiswa kweNaltrexone) Ulungelelaniso I-RTX (i-resiniferatoxin) Isitofu se-epidural Ph II I-RTX (i-resiniferatoxin) Indlela ye-Intra-articular Ph II

Ukuhanjiswa kweLymphatic
IiNkqubo eziPhambili (Isalathiso)	Isigaba II
Sofusa® I-anti-TNF (Autoimmune RA) Ph I Sofusa® i-anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), iMelanoma) Ph I Sofusa® anti-CTLA-4 (Imelanoma) Ph I